Onychomycosis, or toenail fungus, is a relatively common problem that is not only embarrassing and uncomfortable, but can lead to permanent nail damage and limited mobility in some people. Currently, there are several topical remedies available both as a prescription as well as over-the-counter, with varying degrees of success rate. Many of my patients prefer to try these topical medicines first, either due to the relatively mild nature of their nail fungus, or due to a desire to avoid the potential side effects of some of the oral anti-fungal medications.
On July 9, 2014, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved Jublia® (efinaconazole 10% topical solution), the first topical triazole approved for the treatment of onychomycosis of the toenails. This newly-approved medication should be widely available by prescription at your local pharmacy in the near future, and is an exciting new option for me to offer my patients who present with toenail fungus.
I encourage everyone who has toenail fungus, or the suspicion of toenail fungus, to first be evaluated by their podiatrist to obtain an accurate diagnosis, and eventually to receive the treatment that is right for them.
Jennifer Saam, DPM
